Pharmafile Logo

Patient Engagement for the Life Sciences

Patient Engagement for the Life Sciences, written by Guy Yeoman and Mitchell Silva with editorial and design support from Cuttsy+Cuttsy, explains the ‘why’ and the ‘how’ of patient engagement. It presents the compelling argument for why life science companies need to embrace and partner with patients and outlining an operating framework for doing it effectively.

Visit www.medipace.com/book to download your copy.

We’re really proud to have been working with Guy Yeoman and Mitch Silva on their new book, Patient Engagement for the Life Sciences. To celebrate the book launch, we’ve been talking to Guy about why patient engagement is so important to pharma. I’m a firm believer and I’m passionate about effective patient engagement. I think it delivers value for the industry, but also for patients and society at large. My background is in the pharmaceutical business. I’ve been working for the last two decades in the industry, and over the last three years I’ve built a patient-engaging capability for a large pharma organisation. So I come with that corporate, strategic background. The co-author of the book, Mitchell Silva, is a patient. He’s a patient expert himself, he’s a EUPATI scholar, and he’s built a virtual patient network for patients with cancer. So between us we bring both perspectives. We demonstrate clearly in the book why the industry needs to change, but also how it needs to change and what operating framework could be put in place that enables effective patient engagement, delivering value for both the industry as well as the patients and allied stakeholders.


This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Another year, another B!

Louise Jones, Cuttsy+Cuttsy's Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.

Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director

Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.

Clinical trial considerations: Why supporting HCPs matters...

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Clinical trial considerations: Why diversity matters...

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Clinical trial considerations: Why digital matters...

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.

Clinical trials explained: Why imagery matters...

Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...

Clinical trials explained: Why health literacy matters...

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...

Clinical trials explained: Why iconography matters...

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy+Cuttsy appoints Harriet Karia as Managing Director

Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.

Using generative AI in healthcare comms - our promise to our clients

It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when...